Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

DMAC

+ Watchlist+ Portfolio

DiaMedica Therapeutics Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$8.38
52-Week Range
$5.25 – $11.00
Market Cap
$463.49M
P/E (TTM)
—
EPS (TTM)
-0.77
Dividend Yield
0.00%
Advanced Metrics
Price/Book
16.18
PEG Ratio
—
Return on Equity
-100.23%
Return on Assets
-56.08%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
4.76
Debt/Equity
0.01
Total Debt
$157.00K
Free Cash Flow
$-18.95M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$428.75M

Market Snapshot

About

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for neurological and kidney diseases. The company's lead product candidate, DM199, is a recombinant human tissue kallikrein-1 protein being studied for acute ischemic stroke and chronic kidney disease. DiaMedica focuses on leveraging the therapeutic properties of the kallikrein-kinin system. The company conducts clinical trials and preclinical research while seeking regulatory approval pathways for its drug candidates.